A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema

Ophthalmology

Volumn 118, Issue 6, 2011, Pages 1107-1118

  Sultan, Marla B ^a,b   Zhou, Duo ^a   Loftus, Jane ^c   Dombi, Theresa ^a   Ice, Kathleen S ^a  

^a PFIZER INC   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EYE PAIN; FATALITY; FEMALE; HUMAN; INTENTION TO TREAT ANALYSIS; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RETINA EDEMA; RETINA MACULA EDEMA; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 79958012399     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2011.02.045     Document Type: Article

References (45)

1. R. Klein, M.D. Knudtson, and K.E. Lee The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXII: the twenty-five-year progression of retinopathy in persons with type 1 diabetes Ophthalmology 115 2008 1859 1868
2. Eye Diseases Prevalence Research Group The prevalence of diabetic retinopathy among adults in the United States Arch Ophthalmol 122 2004 552 563
3. S. Resnikoff, D. Pascolini, and D. Etya'ale Global data on visual impairment in the year 2002 Bull World Health Organ 82 2004 844 851 (Pubitemid 39573742)
4. S. Wild, G. Roglic, and A. Green Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2004 1047 1053 (Pubitemid 38579764)
5. L.P. Aiello, T.W. Gardner, and G.L. King Diabetic retinopathy Diabetes Care 21 1998 143 156 (Pubitemid 28030402)
6. T.W. Gardner, and D.A. Antonetti Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches Curr Diab Rep 8 2008 263 269
7. N. Bhagat, R.A. Grigorian, A. Tutela, and M.A. Zarbin Diabetic macular edema: pathogenesis and treatment Surv Ophthalmol 54 2009 1 32
8. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
9. M.J. Thompson, and M.S. Ip Diabetic macular edema: a review of past, present, and future therapies Int Ophthalmol Clin 44 2004 51 67 (Pubitemid 39392078)
10. B.P. Nicholson, and A.P. Schachat A review of clinical trials of anti-VEGF agents for diabetic retinopathy Graefes Arch Clin Exp Ophthalmol 248 2010 915 930
11. D.R. Senger, D.T. Connolly, and L. Van de Water Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor Cancer Res 50 1990 1774 1778 (Pubitemid 20098819)
12. H. Funatsu, H. Yamashita, and T. Ikeda Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema Ophthalmology 110 2003 1690 1696 (Pubitemid 37025424)
13. H. Funatsu, H. Yamashita, and K. Sakata Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema Ophthalmology 112 2005 806 816 (Pubitemid 40631499)
14. T. Qaum, Q. Xu, and A.M. Joussen VEGF-initiated blood-retinal barrier breakdown in early diabetes Invest Ophthalmol Vis Sci 42 2001 2408 2413 (Pubitemid 32848873)
15. M.J. Tolentino, D.S. McLeod, and M. Taomoto Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate Am J Ophthalmol 133 2002 373 385 (Pubitemid 34171588)
16. A.P. Adamis, and A.J. Berman Immunological mechanisms in the pathogenesis of diabetic retinopathy Semin Immunopathol 30 2008 65 84
17. S. Ishida, T. Usui, and K. Yamashiro VEGF164 is proinflammatory in the diabetic retina Invest Ophthalmol Vis Sci 44 2003 2155 2162
18. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2004 2805 2816 (Pubitemid 40051904)
19. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
20. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
21. M.E. Van Meter, and E.S. Kim Bevacizumab: current updates in treatment Curr Opin Oncol 22 2010 586 591
22. J.B. Gunther, and M.M. Altaweel Bevacizumab (Avastin) for the treatment of ocular disease Surv Ophthalmol 54 2009 372 400
23. M. Michaelides, A. Kaines, and R.D. Hamilton A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 Ophthalmology 117 2010 1078 1086
24. Q.D. Nguyen, S.M. Shah, A.A. Khwaja READ-2 Study Group Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 117 2010 2146 2151
25. P. Massin, B. Mandello, and J.G. Garweg Safety and efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter, phase II study Diabetes Care 33 2010 2399 2405
26. M.J. Elman, L.P. Aiello, R.W. Beck Diabetic Retinopathy Clinical Research Network Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077
27. Macugen Diabetic Retinopathy Study Group A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 2005 1747 1757
28. I.L. Bailey, and J.E. Lovie New design principles for visual acuity letter charts Am J Optom Physiol Opt 53 1976 740 745 (Pubitemid 8033316)
29. F.L. Ferris III, A. Kassoff, G.H. Bresnick, and I. Bailey New visual acuity charts for clinical research Am J Ophthalmol 94 1982 91 96 (Pubitemid 12080556)
30. M.J. Hogan, S.J. Kimura, and P. Thygeson Signs and symptoms of uveitis I. Anterior uveitis Am J Ophthalmol 47 1959 155 170
31. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12 Ophthalmology 98 1991 823 833
32. C.M. Mangione, P.P. Lee, P.R. Gutierrez National Eye Institute Visual Function Questionnaire Field Test Investigators Development of the 25-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 119 2001 1050 1058 (Pubitemid 32652197)
33. EuroQol Group EuroQola new facility for the measurement of health-related quality of life Health Policy 16 1990 199 208
34. A. Dmitrienko, and M.D. Wang Bayesian predictive approach to interim monitoring in clinical trials Stat Med 25 2006 2178 2195 (Pubitemid 43985453)
35. Diabetic Retinopathy Clinical Research Network Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema Ophthalmology 114 2007 525 536
36. B.Y. Kim, S.D. Smith, and P.K. Kaiser Optical coherence tomographic patterns of diabetic macular edema Am J Ophthalmol 142 2006 405 412
37. T. Otani, S. Kishi, and Y. Maruyama Patterns of diabetic macular edema with optical coherence tomography Am J Ophthalmol 127 1999 688 693 (Pubitemid 29266745)
38. J.C. Buabbud, M.M. Al-latayfeh, and J.K. Sun Optical coherence tomography imaging for diabetic retinopathy and macular edema Curr Diab Rep 10 2010 264 269
39. T. Alasil, P.A. Keane, and J.F. Updike Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema Ophthalmology 117 2010 2379 2386
40. F. Forooghian, P.F. Stetson, and S.A. Meyer Relationship between photoreceptor outer segment length and visual acuity in diabetic macular edema Retina 30 2010 63 70
41. A.S. Maheshwary, S.F. Oster, and R.M. Yuson The association between percent disruption of the photoreceptor inner segment-outer segment junction and visual acuity in diabetic macular edema Am J Ophthalmol 150 2010 63 67
42. S.M. Hariprasad, W.F. Mieler, and M. Grassi Vision-related quality of life in patients with diabetic macular oedema Br J Ophthalmol 92 2008 89 92
43. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials Ophthalmology 113 2006 992 1001
44. L.J. Singerman, H. Masonson, and M. Patel Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial Br J Ophthalmol 92 2008 1606 1611
45. Q.D. Nguyen, S.M. Shah, J.S. Heier READ-2 Study Group Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study Ophthalmology 116 2009 2175 2181